Market Research Logo

Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Review, H2 2016

Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Review, H2 2016’, provides in depth analysis on Angiopoietin 2 (Ang 2 or ANGPT2) targeted pipeline therapeutics.

The report provides comprehensive information on the Angiopoietin 2 (Ang 2 or ANGPT2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Angiopoietin 2 (Ang 2 or ANGPT2)
  • The report reviews Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Angiopoietin 2 (Ang 2 or ANGPT2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Angiopoietin 2 (Ang 2 or ANGPT2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Angiopoietin 2 (Ang 2 or ANGPT2) Overview
Therapeutics Development
Angiopoietin 2 (Ang 2 or ANGPT2) - Products under Development by Stage of Development
Angiopoietin 2 (Ang 2 or ANGPT2) - Products under Development by Therapy Area
Angiopoietin 2 (Ang 2 or ANGPT2) - Products under Development by Indication
Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Angiopoietin 2 (Ang 2 or ANGPT2) - Products under Development by Companies
Angiopoietin 2 (Ang 2 or ANGPT2) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Angiopoietin 2 (Ang 2 or ANGPT2) - Companies Involved in Therapeutics Development
Amgen Inc.
AnGes MG, Inc.
Boehringer Ingelheim GmbH
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
MedImmune, LLC
Regeneron Pharmaceuticals, Inc.
RXi Pharmaceuticals Corporation
Silence Therapeutics Plc
Synergys Biotherapeutics, Inc.
Angiopoietin 2 (Ang 2 or ANGPT2) - Drug Profiles
(aflibercept + nesvacumab) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-30/5C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anti-Angiopoietin-1/2 Monoclonal Antibody - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotides to Inhibit Angiopoietin-2 for Retinal Disease and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atu-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-836880 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3127804 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-3617 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-3617 + tremelimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Angiopoietin 2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7716 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trebananib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vanucizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Angiopoietin 2 (Ang 2 or ANGPT2) - Dormant Projects
Angiopoietin 2 (Ang 2 or ANGPT2) - Discontinued Products
Angiopoietin 2 (Ang 2 or ANGPT2) - Featured News & Press Releases
Nov 04, 2014: Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer
Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis
Jun 20, 2014: University of Arizona Cancer Center at St. Joseph’s researcher reports on response of a new treatment for ovarian cancer
Jun 12, 2013: Amgen's Phase III Trial Of Trebananib Meets Primary Endpoint In Recurrent Ovarian Cancer
Nov 28, 2012: CNIO Announces Initiation Of Phase I Clinical Trial Of New Anti-tumour Drug RO5520985
Sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics
Jan 24, 2011: Takeda Initiates Phase III Clinical Trials Of Anti-Cancer Agent AMG 386 In Japan
Jan 24, 2011: Takeda Initiates Phase III Clinical Trials Of Anti-Cancer Agent AMG 386 In Japan
Oct 09, 2010: Amgen Announces Phase II Trial Results Of AMG 386 In Patients With Recurrent Ovarian Cancer
Jun 06, 2010: Amgen's AMG 386 Demonstrates Promising Antitumor Activity In Patients With Recurrent Ovarian Cancer
Apr 13, 2008: Early Data on Amgen's Anti-Angiogenesis Pipeline Molecules AMG 386 Suggests Biologic Activity Across Tumor Types
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Amgen Inc., H2 2016
Pipeline by AnGes MG, Inc., H2 2016
Pipeline by Boehringer Ingelheim GmbH, H2 2016
Pipeline by Eli Lilly and Company, H2 2016
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Pipeline by MedImmune, LLC, H2 2016
Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016
Pipeline by RXi Pharmaceuticals Corporation, H2 2016
Pipeline by Silence Therapeutics Plc, H2 2016
Pipeline by Synergys Biotherapeutics, Inc., H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report